Journal
CELL DEATH & DISEASE
Volume 12, Issue 12, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-021-04377-1
Keywords
-
Categories
Funding
- Fonds Wetenschappelijk Onderzoek (FWO) [1192920 N, 1243121 N, 117300/12N5415N LV, G030616N]
Ask authors/readers for more resources
Recent research has shown that both the initiation and activation transcriptional programs of hepatic stellate cells are active in mice and humans with chronic liver disease. This suggests that molecules involved in both phases are equally important in finding druggable targets for chronic liver disease.
Activated hepatic stellate cells (aHSC) are the main source of extra cellular matrix in liver fibrosis. Activation is classically divided in two phases: initiation and perpetuation. Currently, HSC-based therapeutic candidates largely focus on targeting the aHSCs in the perpetuation phase. However, the importance of HSC initiation during chronic liver disease (CLD) remains unclear. Here, we identified transcriptional programs of initiating and activated HSCs by RNA sequencing, using in vitro and in vivo mouse models of fibrosis. Importantly, we show that both programs are active in HSCs during murine and human CLD. In human cirrhotic livers, scar associated mesenchymal cells employ both transcriptional programs at the single cell level. Our results indicate that the transcriptional programs that drive the initiation of HSCs are still active in humans suffering from CLD. We conclude that molecules involved in the initiation of HSC activation, or in the maintenance of aHSCs can be considered equally important in the search for druggable targets of chronic liver disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available